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1. Introduction
Stem cell transplant research and tissue engineering, in present time, have emerged as a 
legalized and regulated stem cell treatment option globally, but, scientifically, their success 
is unestablished. Novel stem cell-based therapies have evolved as innovative and routine 
clinical solutions by commercial companies and hospitals across the world. Such rampant 
spread of stem cell clinics throughout UK, US, Europe, and Asia reflect the public encour-
agement of benefits to incurable diseases. However, ever growing stem cell therapy devel-
opments need constant dogwatch and careful policy making by government regulatory 
bodies for prompt action in case of any untoward public concern. Therefore, researchers 
and physicians must keep themselves abreast of current knowledge on stem cells, tissue 
engineering devices in treatment and its safe legal limits. With this aim, stem cell scien-
tific developments, treatment options, and legal scenario are introduced here to beginner 
or actively involved scientists and physicians. Introduction to stem cell therapy will pro-
vide basic information to beginner researchers and practice physicians on engineered stem 
cell research concepts and present stem cell therapy federal regulations in different North 
American, European, and Asian countries. FDA, CDC, EU, ICMR government policies in 
different countries includes information on the current legal position, ethical policies, regu-
latory oversight, and relevant laws.
The word “eais-te-am” cell refers to the progenitor cell or human body’s master cell means 
first original embryonic cell with rejuvenating and restorative capability of regenerating any 
body tissue cell(s) typically called as “Fountain of Youth.” Stem cells can divide and develop 
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different cell types during early life and help in repair the body by replenishing the damaged 
cells in disease, wear, and injury.
Stem cell therapy uses mainly human pluripotent stem cells to restore functions of tissues or 
organs, to maintain or repair the damaged human tissues or organs caused by trauma, genetic 
disease, or metabolic disease. The stem cell engineered products are at large available and 
paradigm shift shows a much greater investment in novel stem cell scaffolds, designing new 
matrices, grafts to treat chronic and incurable diseases.
Four major considerations for successful stem cell therapy and research are:
• Why stem cell clinics need regulation and legalization?
• Purpose and global regulatory norms for stem cell research.
• Reliable stem cell treatment and tissue engineering products.
• Concerns on stem cell treatment regulations and role of government approvals.
Stem cell types and need of human embryogenic cell research and tissue engineering are 
introduced in Section 2. Purpose and global regulatory norms for stem cell research are sum-
marized in Section 3. Present status of stem cell therapy and clinical practice limitations or 
alternatives is reviewed with government guidelines in Section 4. Global scenario of stem cell 
clinical centers to treat different diseases and human organs are tabulated in Section 5. Major 
introduction is how government regulatory authorities define policies, frame guidelines, and 
keep watch public concerns and clinical practices at treatment centers globally.
2. Introduction to stem cell
Stem cells are progenitor cells. There are three types of stem cells: adult stem cells (from 
umbilical cord blood), human embryogenic cells (from embryo from fertilized eggs), and 
induced-pluripotent cells (by reprograming adult stem cells to differentiate into specific tis-
sue cells). These stem cells share common properties: (1) survive long periods to make more 
stem cells; (2) up-specialized but capable to develop into specific cells; (3) develop to do spe-
cific work in the body.
2.1. What are human embryonic stem cells?
Human embryonic stem cells were first isolated and cultured in year 1998 to confirm their 
unique capabilities. They can transform into any human tissues up to 200 different cell types 
found in the body. Under the right conditions, they behave as evergreen, everlasting, and able 
to multiply indefinitely to form immortal cell line. This amazing capacity of embryonic stem 
cells to give rise to any type of tissue has intensified the search for adult stem cells to assume 
paracrine functions [1]. Stem cells have plasticity, means they circulate throughout the body 
and reside wherever needed to promote regeneration of local tissue.
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2.2. Why human embryonic stem cells are in active research?
Stem cell research offers great hope to repair serious life-threatening diseases. The first clinical 
trial took place in the United States for spinal cord injury repair [2]. The first European study 
was reported in the United Kingdom for blindness repair [3].
From biologist’s standpoint, embryonic stem cell research offers as a tool to understand the 
tissue maintenance and repair in health, how disease develops, and its possible treatment. The 
molecular basis of embryonic stem cells growing in three-dimensional culture environments 
has explored the molecular control of gut development and associated organs to understand 
the genetic control of fragile-X syndrome. Other example is Parkinson’s disease, currently 
untreatable and life threat.
2.3. What is origin of embryonic stem cell lines?
All human embryonic stem cell lines originate from a 4- to 5-day-old blastocyst. A blastocyst 
is a hollow ball of around 100 cells. Blastocyst is a left over egg from in vitro fertilization (IVF). 
Some blastocysts are implanted into the woman’s uterus, while the rest are stored in a deep-
freezer. After implantation, couple decides what to do with remaining blastocysts. They can 
continue to store blastocysts for research. Only these donated blastocysts are the source of 
human embryonic stem cell lines.
2.4. New embryonic stem cell line for each research project?
For research, cells are harvested from one 4- to 5-day-old blastocyst. Blastocyst cell multiplies 
in the laboratory to create a “cell line” able to produce an infinite number of embryonic stem 
cells. All these cells have same genetic make-up. Many cell lines are kept in not-for-profit stem 
cell banks. Banks supply these stem cells for research all over the world. Existing cell lines are 
also exchanged at no cost between laboratories in the context of research programs, under 
tight legal controls.
3. Purpose and global regulatory norms for stem cell research
3.1. What position do member states take on human embryonic stem cell research?
Different countries have different legislative provisions among different states on human 
embryonic stem cell research.
In the United States of America, 26 states have active stem cell research legislation policy, 
while other states have loose policy or no legislative rules for stem cell research and treatment. 
So far, no state has permitted any stem cell product for medical treatment as valid. FDA only 
approved cord blood-derived hematopoietic progenitor cells (blood forming stem cells) for 
certain indications including certain blood cancers and some inherited metabolic and immune 
system disorders. Last year, a bill HB 810 passed by Texas Governance Springer has taken first 
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lead to legalize stem cell treatment as “Right to Have Trial” as unproven therapies at their 
own risk and cost in its report (https://legiscan.com/TX/text/HB810/2017). Another bill HB 661 
permits chronic ill persons to try early stage approved clinical trial. New bill HB 3236 permits 
companies to charge patients for unproven therapies. Earlier, Obama Governance declared 
policy for operating 570 stem cell treatment clinics across country including Beverly Hills, CA, 
New York, San Antonio, Los Angeles, Austin, Texas, Phoenix, and Scottsdale, AZ [1].
All 18 countries in the European Union (EU) have stem cell research legislative policy involv-
ing human embryonic stem cells, three countries prohibit it (Poland, Latvia, and Slovakia) 
and the rest have no specific legislation [2, 3]. The EU has no competence to harmonize the 
legal situation in Member States. Legislation on cell therapy is based on three directives: (1) 
directive 2003/63/EC defines cell therapy products as clinical products; (2) directive 2001/20/
EC emphasizes clinical trials mandatory for all cell therapy products; (3) directive 2004/23/
EC establishes standard quality, donation safety, harvesting, tests, processing, preservation, 
storage, distribution of human tissues and cells. In year 2008, regulation 1394/2007/EC on 
Advanced Therapy Medicinal Products (ATMP) includes gene therapy medicinal products, 
somatic cell therapy products, and tissue engineered products (by manipulation, change in 
physiological or structural functions for therapeutic use) under Committee for Advanced 
Therapies (CAT) to provide opinion on safety, quality, efficacy of ATMPs acceptable as stem 
cell-based medical product by marketing authorization [4].
3.2. What are regulations and the policy toward the use of human embryonic stem 
cells and stem cell products for research and clinical use?
In view of the different legal situations and practices in US, EU member States and Asia, 
both US and EU have own clear ethical and legal framework on human embryonic stem cell 
research funded from respective budget. Major regulatory consideration in policy is on batch 
consistency, product stability, safety, efficacy, and quality of stem cell-based tissue engineered 
products through pre-clinical, clinical, and marketing authorization.
In US, FDA and CDC government bodies have laid down stringent guidelines on the use of stem 
cell treatment. Food and Drug Authority (FDA) keeps dog watch over the performance, stan-
dard, and any public concern related with stem cell treatment abuse, defective quality, options 
of tissue engineering for right purpose. In case of non-compliance, irregularities, illicit, and 
unlawful gain, FDA warns stem cell center, and may take precautionary or prohibitive action. 
Major stem cell clinics are opened for certain organ diseases to recover them. Notable exam-
ples are bone and joint disease, erectile dysfunction, neck and back pain, oral and maxillofacial 
surgery, tendons, and arthritis [5–10]. For stem cell therapy, FDA approves stem cell clinic for 
transplantation purpose. FDA defines and regulates different stem cell-based therapies and 
different stem cell products for safe use.
Code of Federal Regulation 21 CFR defined sections for use of cell therapy products: IND 
regulations (21 CFR 312), Biologics regulations (21 CFR 600), and cGMP (21 CFR 211), autolo-
gous cells, tissues, cell- or tissue-based products HCT/Ps (CFR, Part 1271) in year 2006. Public 
Health Service Act (PHSA) refers as “361 products” and “351 products.” Food and Drug 
Administration (FDA) codified 361 cells and tissue products for therapeutic use under Good 
Stem Cells in Clinical Practice and Tissue Engineering6
Tissue Practice (GTP) with guidelines how biologic drug and device regulations apply to 
cellular and genetic therapies [11]. FDA developed a regulatory framework in three areas: 
(1) preventing use of contaminated cells or tissues; (2) preventing the cell and tissue con-
tamination by adequate processing; and (3) clinical safety of all cells and tissues. All these 
areas of framework control both cell and tissue-based products as mass produced drugs [12]. 
However, several agencies, like American Red Cross, American Society of Clinical Oncology, 
and Society of Assisted Reproductive Techniques, clarified the role of FDA limited to allo-
geneic tissue transplants to control spread of communicable diseases means the stem cell 
transplantations are medical procedures. FDA division “Center for Biologics Evaluation and 
Research (CBER)” regulates cell-based therapy, and already approved several ApliGraf®, 
Carticel®, and Epicel® products. The manipulated autologous cells for somatic cell therapy 
need approval as investigational new drug (IND). However, ATMP minimally manipulated, 
labeled, or advertised for homologous use, not combined with drug or device, do not require 
FDA approval. Of course, FDA has wide regulatory coverage including isolation of stem cell 
rich fractions for orthopedic use, breast augmentation, and 5-day blastocyst transfer as equiv-
alent drug mass production. In general, regulation applies to cells and tissues (HCT/Ps) used 
for implementation, transplantation, infusion, and transfer into human recipient.
Two regulatory guides for industries were released by FDA. In the year 2007, “Guidance 
for industry: Regulation of HCT/Ps-Small Entity Compliance Guide” and other in the year 
2009, “Guidance for industry on Current Good Tissue Practice and Additional Requirements 
for Manufacturers of HCT/Ps” [13]. Clinical trials using mesenchymal stem cells fall in the 
IND category. In FDA regulation policy, physicians may administer stem cell-based products 
in patients by two ways: (1) compassionate use or expanded access to investigational drugs 
and biological products without interfering conduct of clinical investigations; (2) off-label 
prescription of FDA approved stem cell products at full discretion of physician. A new draft 
21 CFR 1271 15(b) guideline for industry “Same Surgical Procedure Exception” states three 
criteria advised to physicians: (1) autologous use or remove HCT/Ps from individual and 
implant them into same individual; (2) implant the HCT/Ps within same surgical procedure; 
(3) HCT/Ps must remain in their original form (rinsing, cleaning, sizing, shaping, and manu-
facturing is permitted). All guidelines, 21 CFR 1271(a), 14(b), and 15(b) exceptions, prohibit 
the claim of “practice of medicine” of 361 products without FDA compliance. To date, FDA 
has not approved any stem cell medical product in market place. Moreover, physicians claim 
of performing innovative surgical procedures (as practice of medicine art not directly regu-
lated by FDA) falling under regulatory exception mentioned in 21CFR 1271 Section 361 Public 
Health Service (PHS) Act for human cell-tissue-based products (HCT/Ps) in practice of medi-
cine without spreading communicable disease [14]. In contrast, Section 351 of PHS Act defines 
the premarketing review and FDA approval of drugs, biological products or medical devices.
In the year 2014, two new draft guidelines amended 21CFR 1271.10 and 21CFR 1271.20 regard-
ing Section 361 enacted autologous HCT/Ps only if they are “minimally manipulated” for adver-
tisement or labeling purpose (using of water, crystalloids, sterilizer, or storage preservative) 
without any clinical safety concern. For example, lipoaspirate SVF for adipose derived stem cell 
treatments (by autologous HCT/Ps) of Parkinson disease and multiple sclerosis fail to comply 
21 CFR 1271.10 for homologous use because processing HCT/Ps breaks down and eliminates 
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structural cushion and support components so altered original relevant reconstruction, repair, 
or replacement characteristics of stem cells. It puts them in drug, device, and biological product 
361 category requiring premarketing FDA approval. However, combination standards (mini-
mum manipulation and homologous use) allow drugs, device, biological products as exempted 
investigational new drug or device for premarketing approval with assurance of conducting 
premarketing trial with safety and efficacy. Companies can advertise FDA-cleared investiga-
tional new drugs or device exemptions to gain profits from sale in compliance with federal 
regulations without known safety and efficacy of products. For interested readers, “minimal 
manipulation” means “processing that does not alter the original relevant characteristics of tis-
sues related to tissue utility for reconstruction, repair, or replacement.” In the year 2014, third 
draft regulation “HCT/Ps from Adipose Tissue: Regulatory Considerations” states that process-
ing to isolate nonadipose tissue (without subsequent cell culture or expansion) is more than 
minimal manipulation. Stem cell business centers and clinics may operate sale of unproven and 
unlicensed cell-based interventions without FDA compliance using three said guidelines. Now, 
it requires considerable FDA effort to design final regulatory draft.
The current framework in EU was adopted in year 2007 and subsequently renewed as 
HORIZON 2020 for the duration (2014–2020) to frame the EU’s new research and innovation 
program “triple lock system.”
• First and foremost, national legislation is respected—EU projects must follow the laws of 
the country in which research is carried out;
• In addition, all projects must be scientifically validated by peer review and must undergo 
rigorous ethical review;
• Finally, EU funds may not be used for derivation of new stem cell lines, or for research that 
destroys embryos (blastocysts)—including for the procurement of stem cells.
The program operates on a bottom-up basis. European Commission does not publish calls for 
proposals specifically for research using human embryonic stem cells. Scientists propose the 
methods and materials for a particular study. EU research allows fair comparison of differ-
ent stem cell types to find the best cell source for a particular research or clinical application.
Regulatory framework in Asia has no well-defined regulation and policy on stem cell-based 
products and clinical use. It amounts the risk to patients of physical harm and high finan-
cial exploitation. Currently, clinics and pharma companies do not follow clinical trials under 
regulatory framework or have no national guidelines to follow. Some guides were released as 
guidelines to clinical trials shown in Table 1.
3.2.1. Ethical guidelines for biomedical research in India on human subjects: section V
Stem cell research and therapy (by Indian Council of Medical Research, ICMR 2006) defines the 
clinical grade stem cells for clinical trial approved by institution committee for Stem Cell Research 
and Therapy (IC-SCRT) at multinational companies or from abroad. Collaboration is approved 
by hierarchy of National Apex Committee and Institutional Committee for Stem Cell Research 
and Therapy, Institutional Ethics Committee, Drug Controller general of India, Health Ministry 
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Screening Committee, and funding agency. Investigators should assure that stem cell lines are 
in accordance with appropriate Material Transfer Agreement based on country’s guidelines on 
Good Medical Practices. ICMR, Department of Biotechnology laid down “Guidelines for Stem 
Cell Research and Therapy” in the year 2007 on mechanism of review and monitoring research 
Country Current legal position on embryonic cell 
lines
Ethical/regulatory oversight Reference
Austrıa Banned. imported cell lines permissible Austrian Bioethics Commission [24, 25]
(Fortpflanzungsmedizingesetz) 2004 2009 opinion
Bulgarıa Permitted IVF treatment. Bulgarian Centre for Bioethics
Bulgarian Health Act SG83/19,2003. Central Ethics Commission (CEC) [26]
Czech 
Republıc
Reproductive cloning is banned Czech R&D Council [15]
Fınland Permitted IVF embryos, somatic Medical Research Act 2001 [27]
Cell nuclear transfer Finnish National Advisory Board 
1991
France Permitted research Agence de la Biomédicine [20, 28]
Fr National Committee of Ethics
Germany Permitted research Embryonenschutzgesetz) 1991 [22]
2002 Stem Cell Act Central Ethics Commission (ZES) [29–31]
Greece Permitted IVF embryos Hellenic National Bioethics 
Commission
[32]
Law 3305/2005 National Transplantation 
Organization
Ireland No specific legislation Irish Council of Bioethics (ICB), 2002
Assisted Human Reproduction 
Report
[33]
Italy Permitted imported stem cell lines Law 40
Comitato Nazionale per la Bioetica) [34]
Lıthuanıa Prohibited any embryo research Law on Ethics of Biomedical 
Research
Lithuanian Bioethics Committee 
(LBC)
[35]
Portugal Permitted cell lines from IVF embryos Law 32/2006 medically assisted 
procreation
[36]
Spaın Regulatory framework embryonic stem cells Law 14/2007 for embryo theranostics [37, 38]
Sweden Embryonic cells from IVF/SCNT Act on Genetic Integrity 2005 [39]
UK HEFA regulated stem cell research only Fertilisation and Embryology 
Act 2001
[40]
USA, Canada Stem cell clinics for limited use 21CFR 1271 sections [41]
Table 1. Present rules, restrictions, and regulatory mandate enforced in European and Western world.
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and therapy at national level and institution level. Central Drug Standards Control Organization 
(CDSCO) defined guidelines on new biological/biotechnology products. However, regulation of 
stem cell products as drugs does not exist for clinical trials. As a result, national committee is pro-
posed as “Cell Biology Based Therapeutic Drug Evaluation Committee” by ICMR to approve the 
therapeutic products of human gene manipulation, xerotransplant technology, and stem cells in 
market since year 2011. However, till date no registration requirement technical guidelines of 
human stem cell-based products are formulated.
3.2.2. International unanimous opinion
International Society of Stem Cell Research (ISSCR) and Hinxton group have published 
“guidelines on clinical translation of stem cell” to emphasize: (1) quality controlled stem cells 
with known characteristics; (2) a priori information of delivery efficacy, safety of stem cells 
in animal model; (3) peer reviewed clinical protocols in pre-clinical research; (4) awareness 
of tumorigenic risk without evidence of clinical benefit evidences at the time of voluntary 
informed recipient consent to perform clinical trial [15]. In spite of all, ISSCR recommenda-
tions remain as undefined code of professional conduct to assure safety due to no harmony 
between laboratory-based research and use of approved stem cell-based products with policy 
differences in different continents [16]. Legislation must regulate scientific progress from lab 
to clinic in public interest. Public must have confidence in clinical benefits. The public inter-
ests may be protected by guidelines for: (1) stem cell-based product is safe, pure, potent for 
general practice GTP, GMP, and GCP requirements; (2) pre-clinical evidence available on 
proof-of-principle and safety in animal models; (3) new non-invasive biodistribution moni-
toring by markers and tumors for clinical trials; (4) preference to patient safety by risk-based 
approach in granting regulatory approval with conditional marketing authorization.
3.3. How much have the US and EU spent on human embryonic stem cell research?
In the years 2007–2017, the EU has funded 27 collaborative health research projects involving 
the use of human embryonic stem cells with an EU contribution of about €157 million. Human 
embryonic stem cell research projects represent approximately one-third of health projects on 
all forms of stem cells.
In addition, the European Research Council has funded 10 projects for an EU financial contri-
bution of about €19 million, and there have been 24 Marie Skłodowska-Curie actions involv-
ing human embryonic stem cell research worth €23 million.
4. Stem cell treatment and tissue engineering products
4.1. Stem cell therapy: a success or a myth
Stem cell treatment is a new option of organ transplantation or tissue and cell transplantation. 
Stem cells in culture behave differently from the tissue cells behave inside body. As a result, the 
progenitor cells and embryonic cell behavior entirely depends on media conditions, physiology of 
cultured cells, environment of breeding, action of added growth factors, vital molecules, additives, 
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antibiotics, bioactive proteins, colony stimulating factors, cell division regulatory factors, gene reg-
ulation, signal molecules, enzymes, hormones, and energy available to intracellular metabolism. 
All these factors function and act in unison for stem cell treatment to become success in regen-
erative medicine otherwise stem cells do not grow in the desired manner due to one or the other 
deficiency and stem cell treatment becomes a myth [16, 17].
Any product derived from stem cells or containing stem cells is referred as “stem cell-based 
product” (SCBP), including tissue engineering biomaterials in cell- and tissue-based therapy. 
Around the world, autologous stem cell clinics or hospitals are spreading in China, India, Mexico, 
Panama, Ukraine, European Union member states to perform stem cell facelifts, sport ortho-
pedics, breast augmentation, treatment of muscle dystrophy, Alzheimer’s disease, Parkinson’s 
disease, and multiple sclerosis. In US alone, development of tissue engineering methods have 
shown significant progress in success of stem cells as therapeutic tools of regenerative medicine 
in different states of Ohio, Kansas, Minnesota, Wisconsin, and Mayo. These clinics and centers 
maintain in vitro stem cells in cultures that can be transplanted by fixing them at desired site 
in Matrigel®. With time, stem cells grow in the desired pre-programed manner and regenerate 
the defective part of the tissue or the organ [18]. Stem cell treatment centers charge prospective 
patients privately for simple stem cell therapy by bone marrow or peripheral blood liposuc-
tion, enzyme digestion, ultrasonic cavitation to prepare stromal vascular fraction (mixture of 
fibroblasts, endothelial progenitor cells, pericytes, mesenchymal stroma cells, and adipocytes) 
as therapeutic injection given to said patients or industries manufacture commercial stem cell 
therapy products without any product regulatory information to patients.
For clinical and commercial use, regulatory challenges are safety testing, in vitro functional assays, 
potency assays, pre-clinical, or clinical trials. The safety testing includes assays for microbial, fun-
gal, endotoxin, mycoplasma, viral contamination, karyotyping testing, and enriched cell popula-
tion. In vitro functional and potency assays act a surrogate measure of clinical effectiveness and 
validity to meet standards and control. In support, pre-clinical trial on experimental toxicity ani-
mal models such as immuno-compromised or tumorigenic animals, in vitro manipulation, admin-
istration route, and clinical trials with complete safety and sound ethics are necessary [19]. These 
characteristics establish the potential of these cells for tissue repair after injury or disease so called 
“stem cell therapies” as stem cell medicinal products made out of minimal manipulation of any tar-
get cell type destined for clinical application to improve defective function in the body. Presently, 
human embryonic stem cells (hESCs) are used in 13% of cell therapy procedures; fetal stem cells 
in 2%, umbilical cord stem cells in 10%, and adult stem cells in 75% of treatments [20]. Any use of 
such cell-based medicines is subject to authorization and controls, including their manufacture.
4.2. Clinical development for first-in-man study plan
Study design should demonstrate safety endpoints, efficacy, and its action for proposed clinical 
trial of new investigational medicinal product (EMEA/CHMP/SWP/28367/07). Safety endpoints 
may be defined on theoretical basis or any toxicity endpoint. The efficacy assessment should be 
related to pharmacodynamic effect of ATMP. A safe and minimal effective treatment dose should 
be identified. The presence of stem cells intended at desired location should be investigated by 
selected differentiation biomarkers to facilitate in vivo monitoring the stem cells during the time 
of administration in patients and their follow-up in vivo effect to establish long-term efficacy.
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4.3. Are there alternatives to embryonic stem cells?
Embryonic stem cells have peculiar properties and functions uncommon in other natural cell 
types. Induced-pluripotent stem cell discovery as an alternative was awarded Nobel Prize in 
the year 2012 confirming many similar properties common with embryonic stem cells [21]. 
These cells are in use since then for drug development and screening new medicines. It is 
believed that drug development will be up to the clinical standard for therapeutic purposes 
in the future. In recent years, development of induced-pluripotent stem cells has opened new 
vista of stem cell restoration, repair, rejuvenation, and treatment research as adjuvant therapy.
There are various types of “tissue-specific” or “adult” stem cells. These cells are useful in spe-
cific applications. They make the limited number of cells found in the tissue from which they 
were isolated. So, they are limited in their potential as a clinical application of research. The 
expansion of adult stem cells in culture may be the answer, but extensive cultures of human 
adult cells may change their intrinsic properties in vivo, rendering them unfit for restoring 
injured or diseased tissue in patients.
5. Concerns on stem cell treatment regulations
There are concerns raised in the media about uncertain differentiation and matched neotis-
sue functions after stem cell therapy treatment. The unconfirmed outcome of new techniques 
offers new possibilities of successful treatment in patients with difficult or untreatable condi-
tions. Stem cell therapy techniques have benefits and risks. Specific rules were introduced in 
the European Union (EU) in 2007 [22] to ensure appropriate authorization, supervision, and 
control of cell therapy medicines to reduce and manage the risks.
Recent media reports highlight the need of public authorities’ attention to enforce their legal 
responsibilities in favor of patients taking restricted or limited treatment in compliance with 
relevant quality standards, material authenticity, treatment protocols, and supervised patient 
follow-up measures. The protection of patients is the core rule. Safety and efficacy of stem cell 
transplant products rule the quality and engineered tissue manufacturing of these products 
that are set out in good-manufacturing-practice (GMP) requirements. These are globally rec-
ognized standards for quality assurance in the production and control of stem cell products. 
Security and control of medicines derived from stem cell manipulation is tightly controlled 
by the FDA in US and EU [23].
Present time, manufacturers avoid compliance with quality standards. Inappropriate unap-
proved treatment definition or reclassification without mandate of competent authorities for 
control of stem cell products, may expose patients to cross-contaminated cell preparations, 
and result in short- and long-term risks to individual patients.
5.1. How is stem cell treatment clinics regulated in different countries?
In a very short span of 10 years, over 600 stem cell clinics were opened with unproven claims 
and unapproved treatment definition in the name of some benefits to individual diseases. 
Competent authorities in different countries have laid down ethical or regulatory policies.
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Globally, the present major focus is on stem cell therapy in finding new options of incurable 
diseases with following objectives:
• to promote advances in the treatment of infertility
• to increase knowledge about the causes of congenital disease
• to increase knowledge about the causes of miscarriages
• to develop more effective techniques of contraception
• to develop methods for detecting the presence of gene or chromosome abnormalities
• to increase knowledge about the development of embryos
• to increase knowledge about serious disease
• to enable any such knowledge to be applied in developing treatments for serious disease.
Licensed research is permitted on embryos created in vitro for its limited use in fertility treatment 
research within 14 days of harvesting cells. Human Reproductive Cloning Act (2001) does not 
permit cell nuclear replacement, or any other technique, to create a child or human reproduc-
tive cloning. The Human Tissue Act 2004 [42] regulates the use of human biological materials.
5.1.1. Ethical and regulatory oversight
The regulatory Human Tissue Authority (HTA), the HFEA and the Medicines and Healthcare 
products Regulatory Agency (MHRA), Gene Therapy Advisory Committee (GTAC) are research 
ethics bodies examine and issue reports on ethical issues relating to stem cell research [43].
5.2. Major concerns of stem cell therapy and loopholes in stem cell research
Major concerns are:
• Where do the embryos come from to create stem cell lines for clinical use?
All the human embryonic stem cell lines currently in use come from 4- to 5-day-old embryos 
left over from in vitro fertilization (IVF) procedures. In IVF, researchers mix a man’s sperm 
and a woman’s eggs together in a lab dish. Some of those eggs get fertilized. At about 5 days, 
the egg divides to become a hollow ball of roughly 100 cells called a blastocyst. These early 
embryos (blastocyst) are implanted into the woman’s uterus to develop pregnancy.
For research, unused blastocysts are stored in the IVF clinic freezer for following use in future:
• Continue paying to store the embryos in freezer
• Defrosting the embryos, which destroys them, so, they are kept in freezer
• Donation of the embryos for supervised adoption
• Choice to donate the frozen embryos for research. These donated embryos are the main 
source of human embryonic stem cell lines.
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Some embryonic experimental stem cell lines also come from embryos carrying harmful genetic 
mutations like cystic fibrosis or Tay Sachs disease. These are discovered by genetic testing prior to 
implantation. People who donate leftover embryos for research go through an extensive consent 
process. Under national and international regulations, no human embryonic stem cell lines can 
be created without explicit consent from the donor and without stringent regulatory protocols.
• Do embryonic stem cell lines come from aborted fetuses?
No. Embryonic stem cells only come from 4- to 5-day-old blastocysts or younger embryos 
otherwise it is bad criminal clinical practice.
• Does creating embryonic stem cell lines destroy the embryo?
In most cases, Yes. The hollow blastocyst—source of embryonic stem cells—contains a cluster 
of 20–30 cells called the “inner cell mass.” These are the cells that become embryonic stem 
cells in a lab dish. The process of extracting these cells destroys the embryo. There is a second 
method that creates embryonic stem cell lines without destroying the embryo. Instead, scien-
tists take a single cell from a very early stage IVF embryo and can use only one cell to develop 
a new line. The process of removing one cell from an early stage embryo has been done for 
many years as a way of testing the embryo for genetic predisposition to diseases such as Tay 
Sachs. This process is called “preimplantation genetic testing.”
5.3. Alternatives of embryonic stem cells
New alternatives are emerging to replace controversial embryonic stem cells. Notably, adult 
stem cells, pluripotent cells are promising sources.
• Are adult stem cells as good—or better—than embryonic stem cells?
Adult stem cells unlike embryonic stem cells can grow only to follow certain cell paths. The 
adult stem cells do not grow indefinitely in the lab, unlike embryonic stem cells, and they are 
not as flexible in the types of diseases they can treat. To establish the claims, large trials with 
both adult and embryonic stem cells are needed to know the value of adult stem cells.
• Do iPS cells eliminate the need to use embryos in stem cell research?
Induced-pluripotent stem cells, or iPS cells, represent another type of cells that could be 
used for stem cell research. The iPS cells are adult skin cells. They can be genetically “repro-
gramed” to appear like embryonic stem cells. The technology to generate human iPS cells was 
pioneered by Shinya Yamanaka in 2007 [44].
• Stem cell research may not lead to human cloning because significant regulatory and advi-
sory body has restrictions on reproductive cloning throughout world.
5.4. Scope of stem cell therapy: what clinics offer benefits from stem cell therapy?
Stem cell therapy, in some clinics, is making claims of healing based on new investigational 
personalized trials. Some clinical conditions are claimed to have limited benefit from stem cell 
therapies in recent years are mentioned in Table 2.
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Disease/Problems Benefits claimed Stem Cell Clinics posted on Internet webpages*
Knee and Hip 
problems
Disc degeneration
Ligament tears
Partial ossification
Partial ligament 
repair
https://www.villarbajwa.com/stem-cell-therapy-hip.shtml
https://www.wellmark.com/Provider/MedpoliciesAndAuthorizations/
MedicalPolicies/policies/Stem_Cell_Ortho.aspx
http://www.observer.com/2016/06/stem-cells-andrews-institute/
https://www.regenexx.com/the-regenexx-procedures/
knee-surgery-alternative/
https://articles.mercola.com/sites/articles/archive/2017/06/04/stem-cell-
therapy-repair-regenerate-body.aspx
Blood transfusion Increased counts https://www.cancer.net/navigating-cancer-care/how-
cancer-treated/bone-marrowstem-cell-transplantation/
what-stem-cell-transplant-bone-marrow-transplant
Back arthritis/
spine disease
Partial ossification http://www.jfas.org/article/S1067-2516(16)00027-2/fulltext
https://www.ncbi.nlm.nih.gov/pubmed/17598490
https://stemcellres.biomedcentral.com/articles/10.1186/scrt81
Pain Treatment Improved ECM https://www.stemcellcenters.com/conditions/orthopedic- 
pain-management/
https://www.stemcellcenters.com/conditions/neuropathy-pain/
Neck arthritis Partial ligament 
repair
https://www.stemcellfusion.com/post/stem-cell-therapy-for-neck-arthritis/
https://r3stemcell.com/conditions/shoulder-and-elbow-arthritis/
Shoulder, 
elbow, and hand 
problems
-do- http://sportssurgerychicago.com/alternative-shoulder-replacement-stem-cell-
therapy-westchester-oakbrook-hinsdale-il/
www.newyorkhandsurgery.com/services.html
Anti-aging and 
skin rejuvenation
Better skin looks http://www.startstemcells.com/anti-aging-treatment-naturally.html
Lupus 
Erythromatosus
https://www.regen-center.com/lupus.html
Asthma Better physiological http://stemcellrevolution.com/currently-studying/pulmonary/asthma/
COPD improvement http://www.startstemcells.com/COPD-treatment.html
Crohn’s Disease Abdominal pain 
relief
http://www.startstemcells.com/crohns-disease-treatment.html
Erectile 
Dysfunction
Better eraction https://dasilvainstitute.com/stem-cell-therapy-erectile-dysfunction/
Fibromyalgia Softer muscle, 
joints
http://renovationstemcellinstitute.com/stem-cell-treatment-fibromyalgia
Kidney Disease Improved KFT https://www.kidneycancer.org/get-information/
therapies-for-advanced-kidney-cancer/
www.neuralstem.com/cell-therapy-for-sci
https://lozierinstitute.org/
written-testimony-of-david-a-prentice-ph-d-in-support-of-sb-334/
www.medicalnewstoday.com/articles/264892.php
https://www.stemcellmexico.org/kidney-disease-treatments
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For investigational treatment, consumers need to discuss with doctor to know the potential 
risks and benefits out of SCBP-based treatment with clear information of mandatory EU or 
FDA or country approval and regulation for clinical trial study before giving consent to par-
ticipate in study. Consumers often do not know about SCBP product safety and efficacy out-
side EU and USA. Consumers should be aware of regulatory authority guidelines and safety, 
efficacy regulations (risk/benefit evaluation) covering SCBPs in countries before taking deci-
sion of treatment in those countries. Safety concerns of SCBPs mainly are: possible cell migra-
tion from site of administration to differentiate into inappropriate cell types at unexpected 
tissue sites, excessive new cell growth and tumor, or cancer development.
In nutshell, there is a mixed claim of stem cell therapy success, because of unfounded the-
ory, trials, misguided treatments, and no clinical established research to justify the therapy 
Disease/Problems Benefits claimed Stem Cell Clinics posted on Internet webpages*
Multiple Sclerosis
Parkinson’s 
Disease
Loss in lesions
Better motor 
function
https://www.placidway.com/package/3477
http://alsworldwide.org/research-and-trials/category/stem-cells
http://www.healthyhabitswellness.net/stem-cell-regenerative/
http://www.nymag.com/daily/intelligencer/2015/06/gordie-howe-protocol-
stem-cells.html
Osteoarthritis
Osteoporosis
Psoriatic Arthritis, 
Neck Arthritis
Rheumatoid 
Arthritis
Back arthritis and 
spine disease
Pain Treatment
Oral Maxillofacial 
Densistry
TMJ
Slow bone loss
Osteogenesis
Ossification
-do-
-do-
Neural recovery
Bone repair
https://www.hindawi.com/journals/bmri/2014/951512/.pdf
https://www.macquariestemcells.com/stem-cell-treatment-for-arthritis/
www.drlox.com/
https://treatingpain.com/treatment/regenexx-stem-cell-therapy
www.greensidevetpractice.co.uk/stem-cell-therapy/
http://ocsportsmed.com/wp-content/uploads/2015/07/trifold.pdf
http://www.cjonline.com/news/2016-12-03/
topeka-physician-adds-adult-derived-stem-cell-treatment-practice
https://www.paindoctor.com/Pain_Treatments
http://www.whatisstemcelltherapy.com/Regenerative-Medicine/
Regenerative-Medical-Technology
https://www.cryo-cell.com/cord-blood-treating-diseases
www.faim.org/why-cant-we-use-our-own-stem-cells
Ulcerative Colitis Colon repair https://www.cirm.ca.gov/
https://www.thenewatlantis.com/publications/
appendix-b-the-promise-of-stem-cell-therapies
http://www.allelebiotech.com/cell-therapy/cell-banking/
Hair loss (in both 
men and women)
Hair growth https://www.bioinformant.com/product/stem-cell-fact-sheet/
https://www.bioinformant.com/product/
guide-accelerated-regulatory-pathways/
http://www.orangecountyhairrestoration.org/stem-cell-therapy-hair-loss-
treatment.html
Regenerative 
medicine
Better wound repir https://books.google.co.in/books?isbn=111997139X
Table 2. Several stem cell therapy clinics claim the benefits are shown on internet websites* (right click active).
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and treatment while federal authorities are plagued by false promises of medical experts 
under influence of stem cell and tissue engineering product manufacturers. Investigators and 
researchers have to lot of homework and hard efforts to solve this problem.
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